Protara Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Protara Therapeutics, Inc. (TARA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TARA insiders buying or selling?
In the last 12 months, Protara Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 3 sales ($1.0M) — net selling of $1.0M. Since July 2020, Trabud has recorded 51 Form 4 filings for TARA: 20 buys ($7.2M) and 31 sells ($4.6M).
Source: SEC EDGAR Form 4
What stands out
- No Protara Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 3 reported open-market sales totaled $1.0M.
Key Statistics (July 2020 – Jul 1, 2026)
Total Form 4 filings
51
SEC EDGAR
Insider filers
8
Insider buys (20)
$7.2M
Insider sells (31)
$4.6M
Insider sentiment
Net buyingNet insider flow of $2.6M in net buying since July 2020, and $1.0M in net selling over the last 12 months.
Recent TARA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Jesse Shefferman | CEO and President | Sale | 215.7K | $4.09 | $882.2K | SEC ↗ |
| Apr 9, 2026 | Jacqueline Zummo | Chief R&D Officer | Sale | 1.1K | $5.40 | $6.1K | SEC ↗ |
| Apr 2, 2026 | Jacqueline Zummo | Chief R&D Officer | Sale | 22.6K | $5.26 | $118.9K | SEC ↗ |
| May 19, 2025 | Richard S Levy | Director | Purchase | 20.0K | $3.19 | $63.8K | SEC ↗ |
| May 16, 2025 | Richard S Levy | Director | Purchase | 20.0K | $3.19 | $63.8K | SEC ↗ |
| Mar 28, 2025 | Jacqueline Zummo | Chf Scientific Operations Off | Sale | 21.2K | $4.53 | $96.1K | SEC ↗ |
| Sep 13, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 158.9K | $1.71 | $271.7K | SEC ↗ |
| Sep 10, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 62.0K | $1.84 | $114.3K | SEC ↗ |
| Jul 18, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 11.4K | $2.44 | $27.8K | SEC ↗ |
| Jul 11, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 74.6K | $2.36 | $175.8K | SEC ↗ |
| Jul 3, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 8.3K | $2.12 | $17.6K | SEC ↗ |
| Jun 28, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 64.6K | $2.21 | $142.5K | SEC ↗ |
| Jun 27, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 12.7K | $2.26 | $28.7K | SEC ↗ |
| May 31, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 15.1K | $2.92 | $44.0K | SEC ↗ |
| May 23, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 42.8K | $3.05 | $130.4K | SEC ↗ |
| May 17, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 70.9K | $3.25 | $230.3K | SEC ↗ |
| May 10, 2024 | Opaleye Management Inc. | 10% Owner | Sale | 182.3K | $3.11 | $567.0K | SEC ↗ |
| Dec 30, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 15.5K | $2.71 | $41.9K | SEC ↗ |
| Sep 15, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 23.9K | $3.93 | $93.8K | SEC ↗ |
| Aug 15, 2022 | Jesse Shefferman | CEO and President | Purchase | 9.1K | $3.84 | $34.8K | SEC ↗ |
| Apr 15, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 10.1K | $4.78 | $48.5K | SEC ↗ |
| Apr 8, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 10.1K | $4.78 | $48.5K | SEC ↗ |
| Mar 16, 2022 | Luke M Beshar | Director | Purchase | 10.0K | $4.25 | $42.5K | SEC ↗ |
| Mar 14, 2022 | Luke M Beshar | Director | Purchase | 10.0K | $4.46 | $44.6K | SEC ↗ |
| Jan 31, 2022 | Opaleye Management Inc. | 10% Owner | Purchase | 24.0K | $4.96 | $119.3K | SEC ↗ |
Showing the 25 most recent of 51 Form 4 filings for Protara Therapeutics, Inc..
Most active TARA insiders
- Opaleye Management Inc.24 filings
- Randall Marshall16 filings
- Jacqueline Zummo3 filings
- Jesse Shefferman2 filings
- Luke M Beshar2 filings
Ask anything about TARA insider activity
Use Trabud's AI agent to query Protara Therapeutics, Inc.'s Form 4 history in plain English — "Show me TARA CEO purchases this year" or compare it against any other ticker.
Open the AI agentTARA insider trading FAQ
Are Protara Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Protara Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 3 sales ($1.0M) — net selling of $1.0M. Since July 2020, Trabud has recorded 51 Form 4 filings for TARA: 20 buys ($7.2M) and 31 sells ($4.6M). Over the full record that is net buying of $2.6M.
How many insiders trade TARA stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Protara Therapeutics, Inc.. The most recent filing was accepted on Jul 1, 2026.
Where does Trabud get TARA insider trading data?
All TARA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.